Related Experiment Video
Updated: Jul 26, 2026
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Metabolic dysfunction-associated steatotic liver disease (MASLD): Exploring systemic impacts and innovative therapies
Parag Jain1, Akanksha Jain2, Rohitas Deshmukh3
1Department of Pharmacology, Rungta College of Pharmaceutical Sciences and Research, Bhilai, C.G., India, 490024.
Clinics and Research in Hepatology and Gastroenterology
|March 29, 2025
Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health issue impacting over 30% of adults. Early detection and multidisciplinary care are crucial for managing MASLD and its systemic effects.
Area of Science:
- Hepatology and metabolic diseases
- Public health and epidemiology
- Internal medicine and systemic complications
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD), including its inflammatory form MASH, is a leading cause of chronic liver disease with significant systemic consequences.
- Affecting over 30% of adults, MASLD is driven by insulin resistance, obesity, and dyslipidemia, posing a global health challenge.
- Progression from MASLD to MASH involves hepatic inflammation and fibrosis, potentially leading to cirrhosis, liver cancer, and extrahepatic conditions like cardiovascular disease (CVD) and chronic kidney disease (CKD).
Purpose of the Study:
- To review the systemic nature of MASLD and its pathological mechanisms.
- To highlight the shift in nomenclature from NAFLD to MASLD, emphasizing metabolic etiology.
- To underscore the need for multidisciplinary care and collaborative research to address the increasing burden of MASLD.
Main Methods:
- Literature review focusing on the systemic effects and management of MASLD.
- Analysis of epidemiological data and diagnostic nomenclature changes.
- Discussion of current and emerging therapeutic strategies, including lifestyle modifications and pharmaceuticals.
Main Results:
- MASLD is a global epidemic with increasing prevalence, particularly in younger populations.
- Mechanisms driving MASLD progression involve inflammation, oxidative stress, dysbiosis, and genetic predisposition.
- Lifestyle modifications and specific pharmaceuticals (e.g., GLP-1 receptor agonists, pioglitazone, SGLT-2 inhibitors) show promise in managing MASLD and its systemic outcomes.
Conclusions:
- MASLD necessitates a comprehensive, multidisciplinary approach integrating public health, clinical care, and research.
- Early identification of complications and development of precision medicine strategies are vital for improving patient outcomes.
- Understanding the complex interplay between MASLD and extrahepatic organs requires continued research and collaboration to mitigate its widespread health impact.
